New developments in the prospects for GLP-1 therapy
- PMID: 35107170
- PMCID: PMC8820181
- DOI: 10.1111/bph.15788
New developments in the prospects for GLP-1 therapy
References
-
- Augestad, I. L. , Dekens, D. , Karampatsi, D. , Elabi, O. , Zabala, A. , Pintana, H. , Larsson, M. , Nyström, T. , Paul, G. , Darsalia, V. , & Patrone, C. (2021). Normalisation of glucose metabolism by exendin‐4 in the chronic phase after stroke promotes functional recovery in male diabetic mice. British Journal of Pharmacology, 179 (4), 677–694. 10.1111/bph.15524 - DOI - PMC - PubMed
-
- Brierley, D. I. , Holt, M. K. , Singh, A. , de Araujo, A. , McDougle, M. , Vergara, M. , Afaghani, M. H. , Lee, S. J. , Scott, K. , Maske, C. , Langhans, W. , Krause, E. , de Kloet, A. , Gribble, F. M. , Reimann, F. , Rinaman, L. , de Lartigue, G. , & Trapp, S. (2021). Central and peripheral GLP‐1 systems independently suppress eating. Nature Metabolism, 3(2), 258–273. 10.1038/s42255-021-00344-4 Epub 2021 Feb 15 - DOI - PMC - PubMed
-
- Cui, Q. N. , Stein, L. N. , Fortin, S. M. , & Hayes, M. R. (2021). The role of glia in the physiology and pharmacology of GLP‐1: Implications for obesity, diabetes, and neurodegenerative processes including glaucoma. British Journal of Pharmacology, 179 (4), 715–726. 10.1111/bph.15683 - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical